"For the primary endpoint, all dose groups of BTX 1503 reduced the number of inflammatory lesions from baseline with the highest efficacy obtained for the 5% BTX 1503 QD group (-11.8 lesions). This corresponds to an average percent reduction of 40.54%. The combined vehicle group result was -11.3 lesions or an average percent reduction of 40.15%."
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
-0.010(6.67%) |
Mkt cap ! $274.5M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.0¢ | 14.0¢ | $1.364M | 9.361M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 139 | 5431064 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 171662 | 4 |
View Market Depth
| Last trade - 16.10pm 17/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |